IP Library Granted Patent US 10,603,288
Granted Patent B2
US 10,603,288 · App. 15/948,412 · Granted Mar 31, 2020

Use of cannabinoids in the treatment of epilepsy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,603,288
App. No.
15/948,412
Granted
Mar 31, 2020
Kind
B2
Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Claims (28)

1. A method of treating seizures in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments.

2. The method of claim 1 , wherein the administering reduces total convulsive seizure frequency.

3. The method of claim 1 , wherein the dose of the CBD is increased to about 10 mg/kg/day to about 25 mg/kg/day.

4. The method of claim 1 , wherein the dose of the CBD is increased to about 15 mg/kg/day to about 25 mg/kg/day.

5. The method of claim 1 , wherein the dose of the CBD is increased to about 25 mg/kg/day.

6. The method of claim 1 , wherein the dose of the CBD is increased to about 10 mg/kg/day.

7. The method of claim 1 , wherein the dose of the CBD is increased to about 12 mg/kg/day.

8. The method of claim 1 , wherein the dose of the CBD is increased to about 14 mg/kg/day.

9. The method of claim 1 , wherein the dose of the CBD is increased to about 15 mg/kg/day.

10. The method of claim 1 , wherein the dose of the CBD is increased to about 18 mg/kg/day.

11. The method of claim 1 , wherein the dose of the CBD is increased to about 20 mg/kg/day.

12. The method of claim 1 , further comprising administering clobazam to the patient.

13. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day.

14. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day.

15. The method of claim 1 , wherein the dose of the CBD is increased to about 10 mg/kg/day to about 20 mg/kg/day.

16. A method of treating seizures in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments.

17. The method of claim 16 , wherein the administering reduces total convulsive seizure frequency.

18. The method of claim 16 , wherein the dose of the CBD is increased to about 10 mg/kg/day to about 25 mg/kg/day.

19. The method of claim 16 , wherein the dose of the CBD is increased to about 15 mg/kg/day to about 25 mg/kg/day.

20. The method of claim 16 , wherein the dose of the CBD is increased to about 25 mg/kg/day.

21. The method of claim 16 , wherein the dose of the CBD is increased to about 10 mg/kg/day.

22. The method of claim 16 , wherein the dose of the CBD is increased to about 12 mg/kg/day.

23. The method of claim 16 , wherein the dose of the CBD is increased to about 14 mg/kg/day.

24. The method of claim 16 , wherein the dose of the CBD is increased to about 15 mg/kg/day.

25. The method of claim 16 , wherein the dose of the CBD is increased to about 18 mg/kg/day.

26. The method of claim 16 , wherein the dose of the CBD is increased to about 20 mg/kg/day.

27. The method of claim 16 , further comprising administering clobazam to the patient.

28. The method of claim 16 , wherein the dose of the CBD is increased to about 10 mg/kg/day to about 20 mg/kg/day.

Assignments (5)
CHANGE OF NAME Recorded May 16, 2024
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 067437/0875 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2019
From: GUY, GEOFFREY; WRIGHT, STEPHEN
To: GW RESEARCH LIMITED
Reel/Frame 050145/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2019
From: MEAD, ALICE; DEVINSKY, ORRIN
To: GW PHARMA LIMITED
Reel/Frame 050146/0954 →
ASSET PURCHASE BY WAY OF DEED Recorded Aug 23, 2019
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 050156/0031 →